Freeline Therapeutics Holdings plc - ADR

NASDAQ:FRLN   3:59:53 PM EDT
2.44
+0.14 (+6.09%)
Earnings Announcements

Freeline Reports New Data From Fabry Disease Program

Published: 11/09/2021 21:42 GMT
Freeline Therapeutics Holdings plc - ADR (FRLN) - Freeline Reports New Data From Fabry Disease Program, Pipeline and Company Updates, Including Appointment of Pamela Foulds, Md As Chief Medical Officer, and Third Quarter 2021 Financial Results.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.72

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.67

More details on our Analysts Page.